Emma Essock-Burns1,2, Yan Li1, Janine M. Lupo1, Mei-Yin Polley3, Nicholas Butowski3, Susan M. Chang3, Soonmee Cha, 1,3, Sarah J. Nelson1,4
1Department of Radiology and Biomedical Imaging, UC San Francisco, San Francisco, CA, United States; 2Joint Graduate Group in Bioengineering, UC San Francisco/UC Berkeley , San Francisco, CA, United States; 3Department of Neurological Surgery, UC San Francisco, San Francisco, CA, United States; 4Department of Bioengineering and Therapeutic Sciences, UC San Francisco, San Francisco, CA, United States
Adjuvant anti-angiogenic therapy may alter the presentation of contrast enhancement creating a clinical need for new methods of evaluating response. Dynamic susceptibility contrast enhanced imaging was used to assess vascular changes of patients newly diagnosed with GBM in response to either conventional (XRT+cytotoxic) or adjuvant anti-angiogenic therapy. A decrease in vascularization was observed early in adjuvant anti-angiogenic therapy. Progression-free survival status of patients receiving anti-angiogenic therapy may be dominated by an initial change in leakage, while PFS of patients receiving conventional therapy is not. This work highlights the need for further functional imaging techniques for the evaluation of response.